MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - March 28, 2012) -
MorphoSys AG /
MorphoSys Announces Clinical Milestone from Strategic Alliance
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
has received a milestone payment from Novartis in connection with the
trial application (CTA/IND) and projected initiation of a phase 1
trial. The HuCAL-derived, fully human antibody will be developed
therapeutic area of cancer.
"Today's news marks the first clinical milestone for MorphoSys in
commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys
total, our collaboration with Novartis has resulted in six clinical
date, with two being evaluated in phase 1 and four in phase 2. This
progress clearly underpins the success of this collaboration. Our
antibody pipeline continues to broaden and mature and is one of the
MorphoSys's clinical pipeline now comprises twelve programs in phase 1 and
in phase 2 development including the Company's proprietary programs
which is in a phase 1b/2a trial for rheumatoid arthritis and a phase 1b
multiple sclerosis, MOR208, which is in a phase 1 trial for chronic
leukemia and MOR202, which is in a phase 1/2a trial for multiple myeloma.
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, Ylanthia®,
RapMAT® and arYla® are registered trademarks of MorphoSys.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE